IGF2BP2 variations influence repaglinide response and risk of type 2 diabetes in Chinese population

Acta Pharmacologica Sinica

Volumn 31, Issue 6, 2010, Pages 709-717

  Huang, Qiong ^a   Yin, Ji Ye ^a   Dai, Xing Ping ^a   Pei, Qi ^a   Dong, Min ^a   Zhou, Zhi Guang ^b   Huang, Xi ^c   Yu, Min ^a   Zhou, Hong Hao ^a   Liu, Zhao Qian ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Genetic polymorphism; IGF2BP2; Repaglinide; Type 2 diabetes mellitus

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; REPAGLINIDE; SOMATOMEDIN B BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 2; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHINESE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CARBAMATES; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GENE FREQUENCY; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PIPERIDINES; POLYMORPHISM, GENETIC; RISK FACTORS; RNA-BINDING PROTEINS;

EID: 77953258349     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2010.47     Document Type: Article

References (31)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-53
2. Sladek R, Rocheleau G, Rung J, Dina C, Shen L, Serre D, et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 2007; 445: 881-5
3. Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, Duren WL, et al. A genome-wide association study of type 2 diabetes in finns detects multiple susceptibility variants. Science 2007; 316: 1341-5
4. Zeggini E, Scott LJ, Saxena R, Voight BF, Marchini JL, Hu T, et al. Metaanalysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet 2008; 40: 638-45
5. Zeggini E, Weedon MN, Lindgren CM, Frayling TM, Elliott KS, Lango H, et al. Replication of genome-wide association signals in uk samples reveals risk loci for type 2 diabetes. Science 2007; 316: 1336-41
6. Takeuchi F, Serizawa M, Yamamoto K, Fujisawa T, Nakashima E, Ohnaka K, et al. Confirmation of multiple risk loci and genetic impacts by a genome-wide association study of type 2 diabetes in the japanese population. Diabetes 2009; 58: 1690-9
7. Hinohara K, Nakajima T, Sasaoka T, Sawabe M, Lee BS, Ban J, et al. Replication studies for the association of psma6 polymorphism with coronary artery disease in east asian populations. J Hum Genet 2009; 54: 248-51
8. Wu Y, Li H, Loos RJ, Yu Z, Ye X, Chen L, et al. Common variants in cdkal 1, cdkn2a/b, igf2bp2, slc 30a8, and hhex /ide genes are associated with type 2 diabetes and impaired fasting glucose in a chinese han population. Diabetes 2008; 57: 2834-42
9. Christiansen J, Kolte AM, Hansen TO, Nielsen FC. Igf2 mrna-binding protein 2: Biological function and putative role in type 2 diabetes. J Mol Endocrinol 2009; 43: 187-95
10. Nielsen J, Christiansen J, Lykke-Andersen J, Johnsen AH, Wewer UM, Nielsen FC. A family of insulin-like growth factor ii mrna-binding proteins represses translation in late development. Mol Cell Biol 1999; 19: 1262-70
11. Ng MC, Park KS, Oh B, Tam CH, Cho YM, Shin HD, et al. Implication of genetic variants near tcf 7l2, slc 30a8, hhex , cdkal 1, cdk n2a/ b, igf2bp 2, and fto in type 2 diabetes and obesity in 6,719 asians. Diabetes 2008; 57: 2226-33
12. Groenewoud MJ, Dekker JM, Fritsche A, Reiling E, Nijpels G, Heine RJ, et al. Variants of cdkal1 and igf2bp 2 affect first-phase insulin secretion during hyperglycaemic clamps. Diabetologia 2008; 51: 1659-63
13. Hatorp V. Clinical pharmacokinetics and pharmacodynamics of repaglinide. Clin Pharmacokinet 2002; 41: 471-83
14. Papa G, Fedele V, Rizzo MR, Fioravanti M, Leotta C, Solerte SB, et al. Safety of type 2 diabetes treatment with repaglinide compared with glibenclamide in elderly people: A randomized, open-label, two-period, cross-over trial. Diabetes Care 2006; 29: 1918-20
15. Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT. Cyp2c8 and cyp3a4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide. Br J Clin Pharmacol 2003; 56: 305-14
16. Niemi M, Backman JT, Kajosaari LI, Leathart JB, Neuvonen M, Daly AK, et al. Polymorphic organic anion transporting polypeptide 1b1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther 2005; 77: 468-78
17. Niemi M, Leathart JB, Neuvonen M, Backman JT, Daly AK, Neuvonen PJ. Polymorphism in cyp2c8 is associated with reduced plasma concentrations of repaglinide. Clin Pharmacol Ther 2003; 74: 380-7
18. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502
19. Kang ES, Yun YS, Park SW, Kim HJ, Ahn CW, Song YD, et al. Limitation of the validity of the homeostasis model assessment as an index of insulin resistance in korea. Metabolism 2005; 54: 206-11
20. Spagnoli FM, Brivanlou AH. The rna-binding protein, vg1rbp , is required for pancreatic fate specification. Dev Biol 2006; 292: 442-56
21. Wagner M, Kunsch S, Duerschmied D, Beil M, Adler G, Mueller F, et al. Transgenic overexpression of the oncofetal rna binding protein koc leads to remodeling of the exocrine pancreas. Gastroenterology 2003; 124: 1901-14
22. Saxena R, Voight BF, Lyssenko V, Burtt NP, de Bakker PI, Chen H, et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 2007; 316: 1331-6
23. Wellcome Trust Case Control Consortium. Genome-wide association study of 14 000 cases of seven common diseases and 3000 shared controls. Nature 2007; 447: 661-78
24. Ruchat SM, Elks CE, Loos RJ, Vohl MC, Weisnagel SJ, Rankinen T, et al. Association between insulin secretion, insulin sensitivity and type 2 diabetes susceptibility variants identified in genome-wide association studies. Acta Diabetol 2009; 46: 217-226
25. Moore AF, Jablonski KA, McAteer JB, Saxena R, Pollin TI, Franks PW, et al. Extension of type 2 diabetes genome-wide association scan results in the diabetes prevention program. Diabetes 2008; 57: 2503-10
26. Palmer ND, Goodarzi MO, Langefeld CD, Ziegler J, Norris JM, Haffner SM, et al. Quantitative trait analysis of type 2 diabetes susceptibility loci identified from whole genome association studies in the insulin resistance atherosclerosis family study. Diabetes 2008; 57: 1093-100
27. Horikoshi M, Hara K, Ito C, Shojima N, Nagai R, Ueki K, et al. Variations in the hhex gene are associated with increased risk of type 2 diabetes in the Japanese population. Diabetologia 2007; 50: 2461-6 (Pubitemid 350060646)
28. Van Hoek M, Langendonk JG, de Rooij SR, Sijbrands EJ, Roseboom TJ. Genetic variant in the igf2bp2 gene may interact with fetal malnutrition to affect glucose metabolism. Diabetes 2009; 58: 1440-4
29. Doria A, Patti ME, Kahn CR. The emerging genetic architecture of type diabetes. Cell Metab 2008; 8: 186-200
30. Grarup N, Rose CS, Andersson EA, Andersen G, Nielsen AL, Albrechtsen A, et al. Studies of association of variants near the hhex , cdkn 2a/b, and igf 2bp2 genes with type 2 diabetes and impaired insulin release in 10,705 danish subjects: Validation and extension of genome-wide association studies. Diabetes 2007; 56: 3105-11
31. Ashcroft FM, Rorsman P. Electrophysiology of the pancreatic betacell. Prog Biophys Mol Biol 1989; 54: 87-143